RxDoctor Payments DataLook up a doctor →

Courtney Wuss

Family · Lakewood, NJNPI 1326593286

Payments from drug & device makers

$16,778in general payments, 2019–2025

Across 686 payments — averaging $24.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$7K
  • AbbVie$3K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Alkermes, Inc.$963
  • Johnson & Johnson$864
  • plus $2K from 16 others

What the payments were for

  • Speaking & faculty fees$5,56533%
  • Food & beverage$11,12966%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,778 in reported general payments places this provider in the 95th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$27,803
Medicare patients
93
Services billed
311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl62$97,160
RexultiBrexpiprazole14$19,940
Aripiprazole170$18,778
SecuadoAsenapine12$15,259
Lurasidone Hcl37$12,738
TrintellixVortioxetine Hydrobromide15$6,870
Bupropion XlBupropion Hcl271$5,230
Quetiapine Fumarate164$3,794
Olanzapine OdtOlanzapine11$3,511
Clomipramine Hcl29$2,763
Buspirone Hcl197$2,723
Clozapine30$2,497
Duloxetine Hcl187$2,390
Alprazolam225$1,927
Trazodone Hcl270$1,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$2,585$97,16062 claims
Otsuka America Pharmaceutical, Inc.Rexulti$6,904$19,94014 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$163$6,87015 claims
Almatica Pharma LLCSertraline Hcl$47$1,461236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,692 family providers in New Jersey.

Other family in Lakewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →